Q03181 (PPARD_HUMAN) Homo sapiens (Human)

Peroxisome proliferator-activated receptor delta UniProtKBInterProSTRINGInteractive Modelling

441 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; ) Identical sequences: Homo sapiens: A0A024RCW6

Sequence Features

Add
 71-145Nuclear receptor
 74-94NR C4-type
 111-133NR C4-type
 73-139Zinc finger, nuclear hormone receptor-type
IPR001628PF00105
 243-420Nuclear hormone receptor, ligand-binding domain
IPR000536PF00104

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRange
Ligand binding domain of PPAR delta receptor in complex with a partial agonisthomo-4-mer 1FA;2q5g173-438
Assess
Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP401homo-2-mer B7G;401;2znq170-441
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORShomo-2-mer EPA;3gwx171-441
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORShomo-2-mer 433;1gwx171-441
Assess
Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP204homo-2-mer B7G;K55;2znp170-440
Assess
Human Peroxisome proliferator-activated receptor (PPAR) delta in complexed with a potent and select…homo-2-mer 8RR;K;CL;PGO;JZR;5y7x173-441
Assess
PPARd complexed with a phenoxyacetic acid partial agonisthomo-2-mer 3EQ;JZR;IOD;3peq173-441
Assess
Human Nuclear Receptor-Ligand Complex 1homo-2-mer B7G;VCA;2awh174-441
Assess
Co-crystal structure of an Inhibitor in complex with human PPARdelta LBDhomo-2-mer 9LU;5zxi171-438
Assess
PPARdelta complexed with an anthranilic acid partial agonisthomo-2-mer IOD;DY6;3dy6172-439
Assess
Co-crystal structure of Inhibitor compound in complex with human PPARdelta LBDhomo-2-mer 89L;5xmx172-438
Assess
Crystal Structure of PPAR-delta complexhomo-2-mer L41;3d5f175-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 4monomer 7UY;B7G;PGO;PEG;5u3t170-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 11monomer B7G;7SM;PGO;PEG;5u42170-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 7monomer B7G;7U1;PGO;5u3w170-440
Assess
Crystal structure PPAR delta binding GW0742monomer GW0;GOL;3tkm171-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 3monomer 7V4;B7G;PGO;PEG;K;5u3s170-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 12monomer 7SS;PGO;PEG;B7G;5u43170-439
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 2monomer B7G;7V1;PGO;PEG;5u3r170-439
Assess
Human PPARdelta ligand-binding domain in complexed with GW501516monomer B7G;PGO;PEG;7T1;5u46170-439
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd)LBD in Complex with DN…monomer 9RF;B7G;PE3;6a6p171-440
Assess
Crystal structure of PPAR delta complexed with GW2331monomer IOD;331;B7G;1y0s170-439
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 1monomer 7UJ;B7G;PGO;PEG;K;5u3q173-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 6monomer B7G;7TY;PEG;PGO;5u3v173-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 9monomer B7G;7U7;PGO;PEG;5u3y171-439
Assess
Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd) in Complex with a Ful…monomer B7G;D32;3gz9171-439
Assess
Structure of PPARdelta with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acidmonomer ET1;1BO;3et2172-440
Assess
Structural basis for iloprost as a dual PPARalpha/delta agonistmonomer IL2;3sp9173-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 10monomer 7UA;PGO;PEG;B7G;5u3z172-439
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 14monomer B7G;7SY;PEG;PGO;5u45174-441
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 5monomer 7TV;PGO;PEG;B7G;5u3u172-439
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer WLM;1PE;2xyj173-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 8monomer 7U4;B7G;PGO;PEG;5u3x173-439
Assess
3,4,5-Trisubstituted Isoxazoles as Novel PPARdelta Agonists: Part2monomer GNI;2j14174-440
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer 08S;BOG;2xyw174-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 16monomer 7UG;PEG;PGO;5u41174-439
Assess
Human Nuclear Receptor-Ligand Complex 2monomer CA;B7G;VCA;2b50175-440
Assess
MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORSmonomer 2gwx175-440
Assess
PPAR Delta in complex with azppard02monomer 3OZ;3oz0175-440
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 15monomer 7UD;PEG;PGO;B7G;5u40174-438
Assess
Human PPARdelta ligand-binding domain in complexed with specific agonist 13monomer B7G;PGO;7SV;5u44174-438
Assess
Human Nuclear Receptor-Ligand Complex 1monomer B7G;VCA;2baw175-439
Assess
Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome Proliferator-Act…monomer Z00;BOG;2xyx176-440
Assess
Solution structure of the C4-type zinc finger domain from human Peroxisome proliferator-activated r…monomer ZN;2env72-146
Assess

Homology models

Oligo-stateQMEANTemplateRangeSeq id (%)Ligands
monomer -1.64 3dzy.1.B71-441
65.59ZN;
Assess
monomer -4.64 4nqa.1.A69-438
31.27ZN;
Assess
monomer -4.01 3dzu.1.A71-437
32.61ZN;
Assess
monomer -3.70 4iqr.2.A72-439
29.75ZN;
Assess
monomer -4.49 5uan.1.A72-439
31.27ZN;
Assess
monomer -4.90 4iqr.2.B72-439
29.75ZN;
Assess

Homology models built on isoform sequence

IsoformOligo-stateLigandsQMEANTemplateRangeSeq id (%)
Isoform 2monomerZN;-3.953e00.1.B70-360
64.60
Assess
Isoform 2monomerZN;-4.215uan.1.B73-360
30.28
Assess
Isoform 2monomerZN;-3.924nqa.1.A70-360
34.43
Assess
Isoform 2monomerZN;-4.963dzu.1.A71-360
35.66
Assess
Isoform 3monomerZN;-3.373e00.1.B31-402
65.42
Assess
Isoform 3monomerZN;-3.723dzu.1.A32-398
32.92
Assess
Isoform 3monomerZN;-4.214nqa.1.A28-399
31.69
Assess
Isoform 3monomerZN;-4.625uan.1.A33-400
31.69
Assess
Isoform 3monomerZN;-4.594iqr.2.A33-400
29.25
Assess
Isoform 4monomerET1;1BO;-0.213et2.1.A74-342
100.00
Assess
Isoform 4monomer-2.243dzy.1.B36-343
60.91
Assess